Results 1 to 10 of about 68,172 (115)

PARP inhibitors combined with radiotherapy: are we ready?

Frontiers in Pharmacology, 2023
PARP was an enzyme found in the nucleus of eukaryotic cells that played a crucial role in repairing damaged DNA. Recently, PARP inhibitors have demonstrated great potential in cancer treatment.
Chen Sun, Alan Chu, Rui Song, Shijia Liu, Ting Chai, Xin Wang, Zongwen Liu   +6 more
doaj   +3 more sources

CldU sensitizes BRCA2 reverse-mutated cells to PARP inhibitors [PDF]

Frontiers in Oncology
PARP inhibitors are widely used class of drugs for the treatment of homologous recombination deficient cancers, including BRCA mutated ones. These drugs led to substantial improvement in survival, particularly for patients with BRCA mutated tumors ...
Nawel Zouggari, Nawel Zouggari, Camilla Trugenberger, Camilla Trugenberger, Valentine Du Bois, Wenwen Wang, Giacomo G. Rossetti, Thanos D. Halazonetis, Intidhar Labidi-Galy, Intidhar Labidi-Galy   +9 more
doaj   +2 more sources

PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

Therapeutic Advances in Medical Oncology, 2017
Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer.
Tarra Evans, Ursula Matulonis
doaj   +2 more sources

PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge [PDF]

Experimental and Molecular Medicine
Breast cancer remains the leading cause of cancer-related mortality among women worldwide. Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a critical therapeutic option, particularly for patients with triple-negative breast cancer and other
Weiyun Wang, Chenghui Cai, Sisi Qin, Liujun He, Qinhao Liang, Siyao Tang, Jie Xie, Ting Long, Jing Hou, Wootae Kim, Fei Zhao   +10 more
doaj   +2 more sources

PARP inhibitors in melanoma treatment: potential, challenges, and future directions [PDF]

Frontiers in Oncology
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression.
Angela Anaeme, Karen Moussa, Abdallah N. Mansour, George Nassief, George Ansstas   +4 more
doaj   +2 more sources

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

Frontiers in Pharmacology, 2022
Tumors with BRCA1/2 mutations or homologous recombination repair defects are sensitive to PARP inhibitors through the mechanism of synthetic lethality. Several PARP inhibitors are currently approved for ovarian, breast and pancreatic cancer in clinical ...
Xi Zhang, Xiao Huo, Xiao Huo, Hongyan Guo, Lixiang Xue, Lixiang Xue   +5 more
doaj   +1 more source

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization

Frontiers in Oncology, 2023
Polyadenosine diphosphate-ribose polymerase (PARP) is a key modifying enzyme in cells, which participates in single-strand break repair and indirectly affects double-strand break repair.
Yi Zhang, Lijie Liang, Zheng Li, Ying Huang, Ming Jiang, Bingwen Zou, Yong Xu   +6 more
doaj   +1 more source

Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
The poly (ADP-ribose) polymerase (PARP) inhibitors play a crucial role in cancer therapy. However, most approved PARP inhibitors cannot cross the blood-brain barrier, thus limiting their application in the central nervous system. Here, 55 benzodiazepines
Jiang Yu, Wenfeng Gou, Haihua Shang, Yating Cui, Xiao Sun, Lingling Luo, Wenbin Hou, Tiemin Sun, Yiliang Li   +8 more
doaj   +1 more source

Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods [PDF]

PeerJ, 2020
Background Research has shown that Poly-ADP-ribose polymerases 1 (PARP-1) is a potential therapeutic target in the clinical treatment of breast cancer.
Hongye Hu, Buran Chen, Danni Zheng, Guanli Huang   +3 more
doaj   +2 more sources

Deubiquitination of FBP1 by USP7 blocks FBP1–DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors

Molecular Oncology, 2022
Poly[ADP‐ribose] polymerase (PARP) inhibitors can block DNA single‐strand damage repair and subsequently increase double‐stranded breaks (DSBs) by reducing the activity of the PARP1 protease and by preventing the PARP1 protein from dissociating from ...
Xiang Cheng, Bin Zhang, Feng Guo, Heshui Wu, Xin Jin   +4 more
doaj   +1 more source